There are conflicting epidemiologic data on whether chronic
aspirin (ASA) use may reduce
melanoma risk in humans. Potential anticancer effects of ASA may be mediated by its ability to suppress
prostaglandin E2 (
PGE2) production and activate 5'-adenosine monophosphate-activated
protein kinase (AMPK). We investigated the inhibitory effects of ASA in a panel of
melanoma and transformed melanocyte cell lines, and on
tumor growth in a preclinical model. ASA and the
COX-2 inhibitor celecoxib did not affect
melanoma cell viability, but significantly reduced colony formation, cell motility, and pigmentation (
melanin production) in vitro at concentrations of 1 mmol/L and 20 μmol/L, respectively. ASA-mediated inhibition of cell migration and pigmentation was rescued by exogenous
PGE2 or Compound C, which inhibits AMPK activation. Levels of
tyrosinase, MITF, and p-ERK were unaffected by ASA exposure. Following a single oral dose of 0.4 mg ASA to NOD/SCID mice,
salicylate was detected in plasma and skin at 4 hours and
PGE2 levels were reduced up to 24 hours. Some human
melanoma tumors xenografted into NOD/SCID mice were sensitive to chronic daily ASA administration, exhibiting reduced growth and proliferation. ASA-treated mice bearing sensitive and resistant
tumors exhibited both decreased
PGE2 in plasma and
tumors and increased phosphorylated AMPK in
tumors. We conclude that ASA inhibits colony formation, cell motility, and pigmentation through suppression of
PGE2 and activation of AMPK and reduces growth of some
melanoma tumors in vivo This preclinical model could be used for further
tumor and
biomarker studies to support future
melanoma chemoprevention trials in humans.
Cancer Prev Res; 11(10); 629-42. ©2018 AACR.